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a b s t r a c t
Owing to multidrug resistance, quinolones and third-generation cephalosporins are currently used as
key antibiotics to combat Salmonella organisms. Therapy failure due to reduced ciproﬂoxacin suscepti-
bility has been reported in endemic areas, but also in imported disease. Different bacterial resistance
mechanisms may result in reduced ciproﬂoxacin susceptibility. In this study, the presence and expres-
sion of different resistance mechanisms resulting in reduced minimum inhibitory concentrations (MICs)
for ciproﬂoxacin were evaluated in 23 blood-culture-derived Salmonella enterica serotypes Typhi and
Paratyphi A organisms from ill-returned travellers to Asia. The presence of mutations in the quinolone
resistance-determining region (QRDR) of the gyrA gene as well as an activated efﬂux pump and plasmid-
mediated quinolone resistance geneswas determined. Resistance selection during therapy and the clonal
relatedness of all isolates were established. Efﬂux pump inhibition did not appear to affect the MICs of
ciproﬂoxacin and activity of the efﬂux pump appeared to be speciﬁc for nalidixic acid. Repeated expo-
sure of the isolates to ciproﬂoxacin did not result in a signiﬁcant increase in the MICs for ciproﬂoxacin.
Repetitive sequence-based polymerase chain reaction (rep-PCR) proﬁles identiﬁed ﬁve different geno-
types, but no correlation with resistance was observed. However, a signiﬁcant relation was found with
geographic region; reduced ciproﬂoxacin susceptibility was only found in travellers returning from India
and Pakistan. All isolates with reduced ciproﬂoxacin susceptibility had a mutation at position 83 in the
QRDR region of the gyrA gene. Plasmid-mediated quinolone resistance was not found. These ﬁndings
conﬁrm that the reduced ciproﬂoxacin MIC in S. Typhi and S. Paratyphi A is solely due to an amino acid
‘clust
d thesubstitution in the QRDR
© 2010 Elsevier B.V. an
. Introduction
Resistance of Salmonella spp. to ampicillin, chloramphenicol and
rimethoprim/sulfamethoxazole has been described during the last
0 years. Owing to this multidrug resistance, quinolones and third-
eneration cephalosporins are currently in use as key antibiotics
o combat these multiresistant organisms [1]. As a consequence of
he use of quinolones and cephalosporins, there have been reports
escribing clinical treatment failure following administration of
iproﬂoxacin to patients with typhoid fever owing to reduced
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Open acceer’ of the gyrA gene.
 International Society of Chemotherapy. 
ciproﬂoxacin susceptibility [deﬁned as a minimum inhibitory con-
centration (MIC) of 0.125–1g/mL]. This reduced susceptibility is
found not only in endemic areas but also in developed countries
such as the USA and UK, reﬂecting a global problem [2,3].
Bacterial resistance to quinolones in Salmonella spp. may result
fromdifferent resistancemechanisms. Quinolone resistance is usu-
ally associatedwithmutations in the target site (DNA gyrase),most
commonly in the quinolone resistance-determining region (QRDR)
of the GyrA subunit, conferring resistance to single-step mutants
Open access under the Elsevier OA license.[4]. On the other hand, reduced susceptibility to quinolones is
mostly due to mechanisms such as active efﬂux via efﬂux pumps
as well as alterations in the expression of outer membrane pro-
teins [5]. Plasmid-mediated quinolone resistance has also emerged
in non-typhoidal Salmonella enterica strains resulting in reduced
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iproﬂoxacin susceptibility; this mechanism has not yet been
bserved in typhoidal Salmonella spp. Outer membrane protein-
eﬁcient Salmonella spp. have only been described incidentally,
esulting in increased MICs (>200g/mL) for chloramphenicol [6].
Owing to increased travel to endemic areas as well as migrant
orkers originating from endemic countries, The Netherlands is
lso confronted with patients not responding to empirical ther-
py with ciproﬂoxacin. In this retrospective study, S. enterica
erotypes Typhi and Paratyphi A isolates were systematically char-
cterised with respect to the presence and expression of different
echanisms of resistance causing reduced susceptibility to ﬂuo-
oquinolones in 23 consecutive patients (travellers and migrant
orkers) diagnosed at the Institute for Tropical Diseases ofHarbour
ospital–Rotterdam (The Netherlands) with blood culture-derived
. Typhi or S. Paratyphi A infection.
. Materials and methods
.1. Bacterial isolates
In total, 23 Salmonella isolates (S. Typhi from 11 individu-
ls and S. Paratyphi A from 12 individuals) were collected from
onsecutive patients attending the Institute for Tropical Diseases
uring the period January 2002 to August 2008. All isolates
ere derived from positive blood cultures. Isolates were initially
dentiﬁed biochemically, followed by conﬁrmation using speciﬁc
ntisera. Serotype determination was performed at the National
nstitute for Public Health and the Environment (RIVM) (Bilthoven,
he Netherlands).
ig. 1. Genotyping of 23 isolates by repetitive sequence-based polymerase chain reaction
esistance-determining region.timicrobial Agents 37 (2011) 240–243 241
2.2. Antimicrobial susceptibility
Susceptibility of the isolates was determined using the VITEK-
2 system (bioMérieux sa, Marcy l’Etoile, France). MICs for nalidixic
acid and ciproﬂoxacin were determined by the microbroth dilution
technique. All tests were performed according to Clinical and Lab-
oratory Standards Institute (CLSI) guidelines where applicable. For
in vitro detection of efﬂux pump expression, a two-step dilution
series of the antibiotics nalidixic acid, ciproﬂoxacin and chloram-
phenicol was made to detect the MIC in the absence and presence
of the efﬂux pump inhibitor (EPI) phenylalanine -naphthylamide
(PAN) (20g/mL). A reduction of the initial MIC by ≥3-step dif-
ference upon exposure to the EPI is an indication for the presence
of an activated efﬂux pump [7].
2.3. Polymerase chain reaction (PCR) screening and sequence
analysis
The QRDR of gyrA was ampliﬁed by PCR using the primers
described by Kariuki et al. [8]. Products resulting from ampli-
ﬁcations were subjected to sequencing using a 3100 ABI Prism
Genetic Analyzer (Applied Biosystems, Nieuwerkerk a/d IJssel,
The Netherlands). Analysis and comparison of nucleotide and
amino acid sequence data were carried out using MegAlign
software (DNASTAR Inc., Madison, WI) and programs avail-
able from the National Center for Biotechnology Information
(http://www.ncbi.nlm.nih.gov). Presenceof theqnrA,qnrB,qnrSand
aac(6′)-Ib-cr genes was determined by PCR [9,10]. The presence of
integronswasdeterminedusing themethoddescribedby Lévesque
et al. [11].
(rep-PCR) (DiversiLab®). MIC, minimum inhibitory concentration; QRDR, quinolone


























































c42 R.-J. Hassing et al. / International Journa
.4. Molecular typing
Clonal relatedness of all the isolates was established using
he repetitive sequence-based PCR (rep-PCR) DiversiLab® Micro-
ial Typing System (bioMérieux) according to the manufacturer’s
nstructions. Isolates with ≥95% identical proﬁles were considered
o be closely related.
. Results and discussion
During the last decade, treatment failures with ciproﬂoxacin
ave been increasingly reported. These failures have been asso-
iated with infection with S. Typhi and S. Paratyphi A strains
hat are resistant to nalidixic acid with decreased susceptibility
o ciproﬂoxacin [2,3,12]. Studies describing mechanisms of ﬂu-
roquinolone resistance demonstrate only one or two speciﬁc
echanisms.However, severalmechanismsof resistance can result
n reduced susceptibility to ciproﬂoxacin [4]. Moreover, a combi-
ation of resistance mechanisms could also lead to enhancement
f each of the separate mechanisms resulting in increased MICs. As
entioned previously, studies describing a systematic analysis of
uoroquinolone resistance mechanisms in different S. Typhi and S.
aratyphiA isolates are rare [13]. Therefore,wehave systematically
valuated the presence and expression of different mechanisms
f resistance resulting in reduced MICs for ciproﬂoxacin in 23
almonella clinical isolates.
Of the 23 isolates, 14 (60.9%) were resistant to nalidixic acid
NALR) and displayed reduced MICs for ciproﬂoxacin ranging from
.25g/mL to 2g/mL, except for one isolate (6838) that had a
iproﬂoxacin MIC of 32g/mL. The remaining nine isolates (39.1%)
ere all nalidixic-acid-susceptible (NALS) and had low MICs for
iproﬂoxacin (≤0.03g/mL) (Fig. 1). One of themechanisms result-
ng in reduced susceptibility to quinolones may be the presence of
ctivated efﬂux pumps. To detect the presence of these pumps, a
henotypic method was applied by determining MICs for nalidixic
cid and ciproﬂoxacin in the presence and absence of the EPI
AN. In most isolates, moderate efﬂux activity was determined
or nalidixic acid resulting in MIC reductions of 3–4 steps in the
resence of the EPI. However, the activity of this particular efﬂux
ump(s) does not appear to affect the MICs of ciproﬂoxacin, indi-
ating that the activity of this pump is speciﬁc, at least for nalidixic
cid. As this phenomenon is not exclusively found in NALR iso-
ates, it is concluded that this speciﬁc efﬂux pump(s) is not causing
he increased MICs for ciproﬂoxacin in the NALR isolates (data not
hown). Patients infected with isolates with reduced susceptibility
o ﬂuoroquinolones react less favourably on the initiated therapy
12]. This might be due to the fact that the strains that are already
esistant to nalidixic acid may require fewer exposures to ﬂuoro-
uinolones to develop high-level resistance to ciproﬂoxacin than
trains that are fully ciproﬂoxacin-susceptible [5].
To check for resistance selection during therapy, a selected
umber of isolates were exposed for two rounds to increasing con-
entrations of ciproﬂoxacin. However, this limited exposure did
ot result in a signiﬁcant increase in the MICs of ciproﬂoxacin.
lso, efﬂux pump activity did not change after these two rounds
f selection/induction by repeated exposure to ciproﬂoxacin (data
ot shown). In fact, the same base level efﬂux pump activity
as observed for chloramphenicol (efﬂux indicator antibiotic) as
as already demonstrated for nalidixic acid. Thus, the impaired
linical response is not due to resistance selection during antibi-
tic treatment but may be due to unfavourable pharmacodynamic
arameters resulting in impaired killing.
Resistance or reduced susceptibility to ﬂuoroquinolones is due
o the presence of active efﬂux pumps, impaired outer membrane
ermeability or gyrase mutations. As efﬂux does not explain the
urrent ﬁndings, all isolates were subjected to sequencing of thetimicrobial Agents 37 (2011) 240–243
gyrA gene. Mutations in the QRDR region of the gyrA gene result-
ing in amino acid substitutions are given in Fig. 1. All NALS isolates
show no mutations in the QRDR region. The NALR isolates all had
mutations at position 83 resulting in a substitution of serine to
phenylalanine or tyrosine.
Isolate 6838,with a ciproﬂoxacinMIC of 32g/mL, had a double
mutation. In addition to the mutation at position 83, a substitu-
tion of asparagine to glycine at position 87 was also demonstrated.
Mutations in gyrA outside of the QRDR were observed both in
NALR and NALS isolates (data not shown). These data are in full
agreement with the data of Nair et al. [14] who demonstrated
that a single gyrA mutation at Ser-83 alone resulted in resis-
tance to nalidixic acid and reduced susceptibility to ciproﬂoxacin
(MICs of 0.125–0.25g/mL). Therefore, it was concluded that Ser-
83 is an important site for determining ﬂuoroquinolone resistance
within S. Typhi and S. Paratyphi A isolates. Complete resistance to
ciproﬂoxacin (MIC>4g/mL) has been reported byGaind et al. [13]
and is due to a double mutation in the QRDR region.
In this investigation, the presence of plasmid-encoded qnr genes
resulting in reduced susceptibility to quinolones in Salmonella spp.
was also studied [15]. Expression of these genes is phenotypically
hard to detect as they have a moderate effect on ciproﬂoxacin
MICs even in combination with the aac(6′)-Ib-cr gene. In the 23
isolates studied, it was not possible to demonstrate the pres-
ence of plasmid-encoded qnr genes or aac(6′)-Ib-cr, indicating that
these qnr-bearingplasmids are ‘host’ speciﬁc. Therefore, theseﬁnd-
ings conﬁrm other reports that the reduced MICs of ciproﬂoxacin
in S. Typhi and S. Paratyphi A are solely due to the amino acid
substitution in the QRDR ‘cluster’. Besides reduced susceptibility
to quinolones, two S. Typhi isolates demonstrated resistance to
ampicillin, chloramphenicol, tetracycline and trimethoprim. One
S. Paratyphi A isolate was resistant to ampicillin, chlorampheni-
col and tetracycline. In the two trimethoprim-resistant S. Typhi
isolates an 800-bp integron cassette was demonstrated, indicat-
ing that the gene involved is probably the dfrA7 gene encoding for
a dihydrofolate reductase [16]. Integrons have been demonstrated
in non-typhoidal Salmonella but only occasionally in S. Typhi [17].
To study the genetic relationship between the NALR and NALS
clusters, all isolateswere analysedusing a commercial rep-PCR sys-
tem. Results of rep-PCR (Fig. 1) showed three different clusters of
8, 2 and 11 isolates as well as 2 unique isolates. In clusters A and
D consisting of 8 and 11 isolates, respectively, susceptibility to the
quinolones was randomly distributed, thereby demonstrating that
resistance to nalidixic acid, i.e. reduced ciproﬂoxacin susceptibility,
isnot linked toadistinct cluster. Isolatesbelonging toclusterAwere
all S. Typhi isolates, whereas cluster D comprised S. Paratyphi A iso-
lates. The only consistent correlation found related to the country
of acquisition of the infection, i.e. resistance to nalidixic acid and
reduced susceptibility to ciproﬂoxacin was only found in travellers
to India and Pakistan, but not in travellers to Indonesia and Cam-
bodia. However, these geographical differences are not always that
clear, asNALR isolates have also been reported inVietnam [2]. How-
ever, based on these data it seems at least indicated to treat patients
returning from India with an alternative antibiotic drug instead of
ciproﬂoxacin.
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